37972-69-3

Basic information

• Product Name: 6-HYDROXY-3-PYRIDAZINECARBOXYLIC ACID MONOHYDRATE
• Synonyms: 6-Hydroxy-3-pyridazinecarboxylic acid monohydrate;6-hydroxy-pyridazine-3-carboxylic acid;6-Hydroxy-3-pyridazinecarboxylic acid;2,3-DIHYDRO-3-OXOPYRIDAZIN-6-CARBOXYLIC ACID, MONOHYDRATE;6-Oxo-1,6-dihydropyridazine-3-carboxylic acid;3-hydroxypyridazine-6-car...;6-oxo-1,6-dihydropyridazine-3-carboxylic acid(SALTDATA: FREE);4-hydroxypyriMidine-2-carboxylic acid
• CAS NO: 37972-69-3
• Molecular Formula: C₅H₄N₂O₃
• Molecular Weight: 158.11214
• EINECS: 220-753-0
• Product Categories: Pyridazine series;pyridazine
• Mol File: 37972-69-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 246 °C
• Boiling Point: 518.5 °C at 760 mmHg
• Flash Point: 267.4 °C
• Appearance: /
• Density: 1.63 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -2.86±0.20(Predicted)
• CAS DataBase Reference: 6-HYDROXY-3-PYRIDAZINECARBOXYLIC ACID MONOHYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXY-3-PYRIDAZINECARBOXYLIC ACID MONOHYDRATE(37972-69-3)
• EPA Substance Registry System: 6-HYDROXY-3-PYRIDAZINECARBOXYLIC ACID MONOHYDRATE(37972-69-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 37972-69-3(Hazardous Substances Data)

Usage

Uses

6-Hydroxypyridazine-3-carboxylic acid is a carboxylic acid derivative and can be used as an intermediate in organic synthesis.

InChI:InChI=1/C5H4N2O3/c8-4-2-1-3(5(9)10)6-7-4/h1-2H,(H,7,8)(H,9,10)/p-1

Upstream product

• 328-50-7 α-ketoglutaric acid 
• 27372-38-9 3-Hydroxy-6-carboxy-4.5-dihydro-pyridazin 
• 13327-27-0 3-hydroxy-6-methylpyridazine 
• 27372-38-9 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 13327-27-0 6-Methylpyridazin-3(2H)-on 

Downstream Products

• 5096-73-1 6-chloro-pyridazine-3-carboxylic acid 
• 1025446-21-2 2-(6-oxo-1,6-dihydropyridazin-3-yl)imidazo[4,5-c]pyridin-4-one 
• 75680-92-1 6-chloro-3-pyridazinecarboxylic acid ethyl ester 
• 63001-31-0 ethyl 1,6-dihydro-6-oxopyridazine-3-carboxylate 
• 65202-50-8 methyl 6-chloro-3-pyridazinecarboxylate 
• 1431296-79-5 methyl 3-((6-oxo-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)pyridazin-1(6H)-yl)methyl)benzoate 
• 1431297-30-1 6-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)pyridazin-3(2H)-one 
• 1571024-41-3 6-(3-(4-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-2-(3-(4-(methylsulfonyl)piperidin-1-yl)benzyl)pyridazin-3(2H)-one 
• 1571033-54-9 6-(3-(4-(difluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)pyridazin-3(2H)-one 

Relevant articles and documents

Synthesis of 3-chloropyridazine-6-carboxylic acid hydrazide and selective hydrazinolysis of 3,6-substituted pyridazines

3-Chloropyridazine-6-carboxylic acid hydrazide (5) was synthesized by employing hydrazine monohydrate and methyl levalinate as starting materials through five steps, including hydrazinolysis. Selective hydrazinolysis of 3,6-substituted pyridazines was investigated.

METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME

The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies

Herein, we described the design and synthesis of a series of pyridazine-3-carboxamides to be CB2-selective agonists via a combination of scaffold hopping and bioisosterism strategies. The compounds were subjected to assessment of their potential activities through calcium mobilization assays. Among the tested derivatives, more than half of these compounds exhibited moderate to potent CB2 agonist activity. Six compounds showed EC50 values below 35 nM, and several derivatives also exhibited significantly enhanced potency and high selectivity at the CB2 receptor over the CB1 receptor. Specifically, compound 26 showed the highest CB2 agonist activity (EC50 = 3.665 ± 0.553 nM) and remarkable selectivity (Selectivity Index > 2729) against CB1. In addition, logPs of some representative compounds were measured to display significantly decreased values in comparison with GW842166X. Furthermore, docking simulations were conducted to explain the interaction mode of this series.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.